- Home
- EPRX
as 12-17-2024 4:00pm EST
Stocks
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.
| Founded: | 2011 | Country: | Canada |
| Employees: | N/A | City: | N/A |
| Market Cap: | 111.1M | IPO Year: | N/A |
| Target Price: | $9.00 | AVG Volume (30 days): | 24.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.20 - $4.08 | Next Earning Date: | 02-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest EUPRAXIA PHARMACEUTICALS INC News
EPRX Breaking Stock News: Dive into EPRX Ticker-Specific Updates for Smart Investing
CNW Group
a month ago
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
PR Newswire
a month ago
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
CNW Group
a month ago
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
PR Newswire
a month ago
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
CNW Group
a month ago
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
PR Newswire
a month ago
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
PR Newswire
2 months ago
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
CNW Group
2 months ago
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
Compare EPRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EPRX EUPRAXIA PHARMACEUTICALS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.